Jeffrey S. Hatfield's Insider Trades & SAST Disclosures
Jeffrey S. Hatfield's most recent trade in Vir Biotechnology Inc was a trade of 16,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 30, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jeffrey S. Hatfield.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vir Biotechnology Inc | Jeffrey S. Hatfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jeffrey S. Hatfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 8,000 | 23,806 (0%) | 0% | 0 | Common Stock | |
| Vir Biotechnology Inc | Jeffrey S. Hatfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 12,054 | 12,054 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jeffrey S. Hatfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 6,027 | 15,806 (0%) | 0% | 0 | Common Stock | |
| Vir Biotechnology Inc | Jeffrey S. Hatfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2022 | 12,810 | 12,810 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jeffrey S. Hatfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2022 | 6,405 | 9,779 (0%) | 0% | 0 | Common Stock | |
| Vir Biotechnology Inc | Jeffrey S. Hatfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 6,748 | 6,748 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jeffrey S. Hatfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 3,374 | 3,374 (0%) | 0% | 0 | Common Stock | |
| Viridian Therapeutics Inc | Jeffrey S. Hatfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 25,000 | 25,000 | - | - | Director Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jeffrey S. Hatfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2020 | 46,500 | 46,500 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges